Humana Stock Surge Explained: Medicare Advantage and Earnings Performance

Humana's stock recently surged by 48% over the past month, reaching approximately $303. This significant increase is attributed to favorable Medicare Advantage rate developments and strong Q1 2026 financial results. Humana's earnings per share (EPS) of $10.31 exceeded market predictions, with revenue leaping 24% from the previous year to $39.65 billion. In contrast, UnitedHealth Group's shares rose by 19% with an adjusted EPS of $7.23, while Cigna Group experienced a modest 2.5% increase despite surpassing earnings forecasts with an EPS of $7.79.

The uptick in Humana's stock largely stems from its extensive exposure to Medicare Advantage plans, which proved advantageous under recent rate adjustments. Conversely, UnitedHealth benefits from a diverse portfolio, including its Optum segment, and Cigna's focus on commercial insurance and pharmacy benefits shows a different growth trajectory. Humana's Q1 results highlighted a beneficial insurance segment benefit ratio of 89% and reaffirmed FY2026 guidance for adjusted EPS of no less than $9 and revenues surpassing $160 billion, according to CEO Jim Rechtin.

Meanwhile, UnitedHealth reported improved quarterly performance, enhancing its medical cost ratio to 84%, and adjusted its annual EPS guidance upwards to over $18.25. Cigna also registered a 5% revenue growth to $68.49 billion with an improved medical care ratio of 80%, aligning with its commercial and pharmacy benefit strategies. Looking at the year-to-date, Humana’s stock increased by 18.5%, closely following UnitedHealth's 17% rise, while Cigna achieved a 4% gain. Over the past year, UnitedHealth led with a 33% increase.

Humana’s current stock surge may indicate a recovery phase rather than a new growth phase as it transitions from a prolonged downturn. Upcoming developments like the October Stars ratings release and the recent MaxHealth acquisition are pivotal factors. Analysts caution that current stock valuations might already account for expected regulatory benefits, emphasizing that sustained growth will depend on continued operational success. Investors may consider cautious positions as upcoming metrics such as the Star Ratings cycle provide further insight for evaluations.